<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029611435093</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029611435093</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Impaired Endothelial-Dependent and Endothelium-Independent Vasodilatation in Patients With Thromboangiitis Obliterans</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Brodmann</surname>
<given-names>M.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1076029611435093">1</xref>
<xref ref-type="corresp" rid="corresp1-1076029611435093"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hafner</surname>
<given-names>F.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1076029611435093">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gary</surname>
<given-names>T.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1076029611435093">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Seinost</surname>
<given-names>G.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1076029611435093">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pilger</surname>
<given-names>E.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1076029611435093">1</xref>
</contrib>
<aff id="aff1-1076029611435093"><label>1</label>Department of Internal Medicine, Division of Angiology, Medical University Graz, Graz, Austria</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1076029611435093">M. Brodmann, Department of Internal Medicine, Division of Angiology, Medical University Graz, A-8036 Graz, Austria. Email: <email>marianne.brodmann@medunigraz.at</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>33</fpage>
<lpage>36</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Background:</title> 
<p>Endothelial dysfunction is the key process in the development of atherosclerosis. The aim of our study was to evaluate endothelial dysfunction measured by the noninvasive technique of Celermajer that plays a role in the pathogenesis of thrombangitis obliterans.</p></sec>
<sec>
<title>Methods:</title>
<p>A total of 36 patients with thrombangitiis obliterans ([TAO]; mean age 44.9 ± 1.3 years) were compared with 30 healthy individuals (mean age 36.1 ± 1.8 years). High frequency ultrasound was used to measure changes in response to reactive hyperemia (leading to flow-mediated endothelium-dependent dilatation) and in response to 0.4 mg sublingual nitroglycerin ([NTG]; leading to NTG-induced, endothelium-independent dilatation).</p></sec>
<sec>
<title>Results:</title>
<p>Patients with TAO showed a lower but statistically not significant flow-mediated dilatation and a statistically significant reduced NTG-induced vasodilatation than the control group.</p></sec>
<sec>
<title>Conclusion:</title>
<p>
Our results suggest that both mechanisms play a role in patients with TAO, the endothelium-independent impaired vasodilatation even in a more significant way than the impaired endothelium-dependent vasodilatation.</p></sec>
</abstract>
<kwd-group>
<kwd>endothelial dysfunction</kwd>
<kwd>thrombangitis obliterans</kwd>
<kwd>flow-mediated-endothelial dependent dilatation</kwd>
<kwd>nitroglycerin</kwd>
<kwd>nitroglycerin-induced endothelium independent vasodilatation</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January/February 2013</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-1076029611435093">
<title>Introduction</title>
<p>Endothelial dysfunction is regarded as the key process in the development of atherosclerosis. It is an early event in experimental studies of atherogenesis preceding the formation of plaques.<sup><xref ref-type="bibr" rid="bibr1-1076029611435093">1</xref>,<xref ref-type="bibr" rid="bibr2-1076029611435093">2</xref></sup> Since the development of a noninvasive measurement of endothelial dysfunction by Celermajer et al, the influence of all known vascular risk factors on endothelial function has been evaluated.<sup><xref ref-type="bibr" rid="bibr2-1076029611435093">2</xref>,<xref ref-type="bibr" rid="bibr3-1076029611435093">3</xref><xref ref-type="bibr" rid="bibr4-1076029611435093"/><xref ref-type="bibr" rid="bibr5-1076029611435093"/><xref ref-type="bibr" rid="bibr6-1076029611435093"/><xref ref-type="bibr" rid="bibr7-1076029611435093"/><xref ref-type="bibr" rid="bibr8-1076029611435093"/>–<xref ref-type="bibr" rid="bibr9-1076029611435093">9</xref></sup> Some studies also exist highlighting the influence of endothelial dysfunction in the process of nonatherosclerotic vascular disorders such as Raynaud phenomenon, immunologically based vasculitis, and thrombangitiis obliterans (TAO).<sup><xref ref-type="bibr" rid="bibr10-1076029611435093">10</xref>,<xref ref-type="bibr" rid="bibr11-1076029611435093">11</xref></sup> The TAO is an arterial occlusive disease which is on one hand a different disease entity than atherosclerosis and on the other hand differs from any immunologically based vasculitis.<sup><xref ref-type="bibr" rid="bibr12-1076029611435093">12</xref><xref ref-type="bibr" rid="bibr13-1076029611435093"/><xref ref-type="bibr" rid="bibr14-1076029611435093"/>–<xref ref-type="bibr" rid="bibr15-1076029611435093">15</xref></sup> It occurs mainly in the small- and medium-sized vessels of young adults with a high history of smoking. The pathogenesis of the disorder is still a matter of discussion and only the positive relationship with smoking is for sure.<sup><xref ref-type="bibr" rid="bibr15-1076029611435093">15</xref></sup> Patients who stop smoking have a good chance of no further progression of the disease. As smoking has a negative influence on regular endothelial function, it can therefore most probably be concluded that endothelial function is deteriorated in patients with TAO. Some studies until now have addressed this matter and mostly shown markers for impaired endothelial function in TAO. The only drawback of these studies is their less number of patients.<sup><xref ref-type="bibr" rid="bibr16-1076029611435093">16</xref><xref ref-type="bibr" rid="bibr17-1076029611435093"/><xref ref-type="bibr" rid="bibr18-1076029611435093"/><xref ref-type="bibr" rid="bibr19-1076029611435093"/>–<xref ref-type="bibr" rid="bibr20-1076029611435093">20</xref></sup>
</p>
<p>The aim of our study was to evaluate in a larger cohort of patients with TAO if endothelial dysfunction measured by the noninvasive technique of Celermajer<sup><xref ref-type="bibr" rid="bibr1-1076029611435093">1</xref></sup> in fact plays a role in TAO. Dealing with this question, to our knowledge, this study is the largest cohort of patients with TAO.</p>
</sec>
<sec id="section2-1076029611435093" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-1076029611435093">
<title>Individuals</title>
<p>A total of 36 patients with TAO (mean age 44.9 ± 1.3years) were compared with 30 healthy individuals (mean age 36.1 ± 1.8 years). Patients were diagnosed for TAO when they met the following diagnostic criteria: history of smoking, onset of vascular disease before the age of 50, infrapopliteal arterial occlusive disease, either upper-limb involvement or phlebitis migrans, and absence of atherosclerotic risk factors other than smoking.<sup><xref ref-type="bibr" rid="bibr12-1076029611435093">12</xref></sup> None of the patients or control individuals had any of the typical vascular risk factors, diabetes, or arterial hypertension. Patients with TAO and controls had started smoking around the age of 20. All our patients with TAO were in remission and showed no activity of their underlying disease as can be seen by baseline inflammatory parameters (<xref ref-type="table" rid="table1-1076029611435093">Table 1</xref>
). Smoking was not allowed on the day of the test. The individuals evaluated had a fasting period for at least 12 hours and no caffeine or tea intake for the same period of time.</p>
<table-wrap id="table1-1076029611435093" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical Criteria for the Diagnosis of TAO</p>
</caption>
<graphic alternate-form-of="table1-1076029611435093" xlink:href="10.1177_1076029611435093-table1.tif"/>
<table>
<thead>
<tr>
<th>Clinical criteria for the diagnosis of TAO</th>
</tr>
</thead>
<tbody>
<tr>
<td> Smoking history</td>
</tr>
<tr>
<td> Onset before the age of 50</td>
</tr>
<tr>
<td> Infrapopliteal arterial occlusive disease</td>
</tr>
<tr>
<td> Either upper-limb involvement or phlebitis migrans</td>
</tr>
<tr>
<td> Absence of atherosclerotic risk factors other than smoking</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1076029611435093">
<p>Abbreviation: TAO, thrombangitis obliterans.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-1076029611435093">
<title>Brachial Artery Vascular Reactivity</title>
<p>High frequency ultrasound (8 MHz transducer, Sequoia system; Acuson, California) was used to measure changes in response to reactive hyperemia (leading to endothelium-dependent flow-mediated dilation [FMD]) and in response to 0.4 mg sublingual nitroglycerin ([NTG]; leading to NTG-induced, endothelium-independent dilatation [NMD]) as described previously.<sup><xref ref-type="bibr" rid="bibr1-1076029611435093">1</xref></sup> The right brachial artery was scanned in longitudinal sections 2 to 15 cm above the elbow, after at least 10 minutes of rest in the supine position. Hyperemia was induced by inflating a pneumatic cuff placed around the forearm to 230 mm Hg for 5 minutes, then deflating the cuff to 0 mm Hg. The artery was scanned before cuff inflation and 1 minute after deflation. After another 20-minute rest, a further control scan was recorded. A single dose of 0.4 mg of NTG was administered sublingually and the brachial artery diameter was recorded 4 minutes afterward. Four cardiac cycles were analyzed for each scan and the measurements averaged. All scans were recorded for later analysis. Diameter measurements were taken end diastole, coincident with R-wave on a continuously recorded electrocardiographic trace.</p>
<p>For the calculation of flow-mediated dilatation, the vessel diameter change of 1 minute after cuff deflation was divided by the average control diameter and expressed as percentage of the first control scan. Endothelium-independent dilatation was calculated as the vessel diameter change at 4 minutes after NTG had been given divided by the average control diameter and expressed as the percentage of the first control scan.</p>
</sec>
<sec id="section5-1076029611435093">
<title>Statistical Analysis</title>
<p>All values are expressed as the mean ± standard error of the mean. Comparison of normally distributed variables was performed by Student test in order to test for differences among the 2 groups. For not normally distributed variables, the Mann-Whitney test was used for comparisons between 2 groups. <italic>P</italic> values less than .05 were considered statistically significant. All calculations were done with SPSS 10.0 for Windows.</p>
</sec>
</sec>
<sec id="section6-1076029611435093">
<title>Results</title>
<p>The characteristics of study individuals are summarized in <xref ref-type="table" rid="table2-1076029611435093">Table 2</xref>
. There was no significant difference besides smoking between the 2 groups. Concerning smoking patients with TAO showed a significant higher percentage in smoking history than the control group (100% vs 20%).</p>
<table-wrap id="table2-1076029611435093" position="float">
<label>Table 2.</label>
<caption>
<p>Patient Characteristics</p>
</caption>
<graphic alternate-form-of="table2-1076029611435093" xlink:href="10.1177_1076029611435093-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">
</th>
<th align="center">Patients (TAO)</th>
<th align="center">Controls</th>
</tr>
<tr>
<th>N = 36</th>
<th align="center">N = 30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>20 (55.6%)</td>
<td>7 (23.3%)</td>
</tr>
<tr>
<td>Females</td>
<td>16 (44.4%)</td>
<td>23 (76.7%)</td>
</tr>
<tr>
<td>Mean age, years</td>
<td>44.9 ± 1.3</td>
<td>36.1 ± 1.8</td>
</tr>
<tr>
<td>Fasting blood glucose, mg/dL</td>
<td>87 ± 13</td>
<td>91 ± 14</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>122 ± 8</td>
<td>123 ± 10</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>77 ± 6</td>
<td>80 ± 6</td>
</tr>
<tr>
<td>Total cholesterin (mg/dL; −200)</td>
<td>176 ± 10</td>
<td>169 ± 9</td>
</tr>
<tr>
<td>HDL cholesterin (mg/dL; &gt;40)</td>
<td>35 ± 2</td>
<td>34 ± 3</td>
</tr>
<tr>
<td>LDL cholesterin (mg/dL)</td>
<td>90 ± 10</td>
<td>91 ± 8</td>
</tr>
<tr>
<td>Triglycerides (mg/dL; −150)</td>
<td>123 ± 18</td>
<td>120 ± 20</td>
</tr>
<tr>
<td>Smokers</td>
<td>36 (100%)</td>
<td>6 (20%)</td>
</tr>
<tr>
<td>Number of cigarettes/day/mean</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Leucocytes (g/L; −11.3)</td>
<td>9.76 ± 0.76</td>
<td>9.41 ± 1.46</td>
</tr>
<tr>
<td>CRP (mg/L; −5)</td>
<td>4.46 ± 0.76</td>
<td>3.97 ± 0.89</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1076029611435093">
<p>Abbreviations: TAO, thrombangitis obliterans; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Patients with TAO showed a lower FMD than the control group. But the difference did not reach statistical significance (<xref ref-type="table" rid="table3-1076029611435093">Table 3</xref>
). Nitroglycerin-induced dilatation did show significant difference between the 2 groups. Compared to the control group, NTG-induced (endothelium independent) vasodilatation was statistically significantly reduced in patients with TAO (<xref ref-type="table" rid="table3-1076029611435093">Table 3</xref>).</p>
<table-wrap id="table3-1076029611435093" position="float">
<label>Table 3.</label>
<caption>
<p>Data FMD and NMD (%)a
</p>
</caption>
<graphic alternate-form-of="table3-1076029611435093" xlink:href="10.1177_1076029611435093-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Patients (TAO)</th>
<th>Controls</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>FMD</td>
<td>5.6972 ± 0.5733%</td>
<td>7.0927 ± 1.0386%</td>
<td>.584</td>
</tr>
<tr>
<td>NMD</td>
<td>12.6515 ± 0.9324%</td>
<td>16.6292 ± 1.0972%</td>
<td>.008</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1076029611435093">
<p>Abbreviations: FMD, flow-mediated dilation; NMD, nitroglycerin-mediated dilation.</p>
</fn>
<fn id="table-fn4-1076029611435093">
<p>
<sup>a</sup> Numbers are n (%).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-1076029611435093">
<title>Discussion</title>
<p>In a disease like thromboangiitis obliterans, which is an arterial occlusive disease but differs in its entity from atherosclerosis and all other immunological vasculitides, the role of the endothelium in the pathogenesis of the disease is the more interesting, especially when regarding the positive and strong relationship of the disease to smoking.<sup><xref ref-type="bibr" rid="bibr12-1076029611435093">12</xref><xref ref-type="bibr" rid="bibr13-1076029611435093"/><xref ref-type="bibr" rid="bibr14-1076029611435093"/>–<xref ref-type="bibr" rid="bibr15-1076029611435093">15</xref></sup>
</p>
<p>The results of our study show a positive relationship to impaired endothelium-dependent vasodilatation (FMD) in patients with TAO, although this difference was not statistically significant. The possible explanation for this phenomenon may be the high rate of non-dilatating individuals among the healthy control group. Our results resemble the results of 2 other studies,<sup><xref ref-type="bibr" rid="bibr16-1076029611435093">16</xref>,<xref ref-type="bibr" rid="bibr17-1076029611435093">17</xref></sup> with the difference that in the above-mentioned studies, the authors found controversial results concerning NMD. In our collective data, NMD was statistically significantly lower in patients with TAO than in the control group. In arteries lined by healthy endothelium increased blood flow causes dilatation of the vessel, via release of endothelium-derived relaxation factor. This mechanism fails in endothelial dysfunction. In contrast, NTG causes vasodilatation by direct action of the smooth muscle, its effect is therefore independent of the endothelium.<sup><xref ref-type="bibr" rid="bibr1-1076029611435093">1</xref></sup> In one article by Joras et al, an insignificant decrease of endothelium-independent vasodilatation was found. The authors therefore concluded a well-preserved muscle cell function in patients with TAO.<sup><xref ref-type="bibr" rid="bibr17-1076029611435093">17</xref></sup>
</p>
<p>Our results suggest that both mechanisms seem to play a role in patients with TAO, the endothelium-independent impaired vasodilatation even in a more significant way than the impaired endothelium-dependent vasodilatation. This indicates also the probability of smooth muscle cell dysfunction of the arterial wall, owing to structural changes in vascular tissues and consequently more rigid vessels. The coincidence of endothelial dysfunction and impaired endothelial-independent vasorelaxation would also be a reasonable explanation why the disease is occurring at such a young age in a people’s collective with only one typical vascular risk factor, that is, smoking.</p>
<p>Besides our results represent data from a cohort of patients with TAO not in an active state of their disease, as much as such a state can be proved by baseline inflammatory parameters. Therefore, the data gained from both, endothelium-dependent vasodilatation and endothelium-independent vasodilatation, can be assumed to be data from a homogenous cohort. This is in contrast to the data published before.</p>
<p>When regarding the influence of typical vascular risk factors like hyperhomozysteinemia who are influencing endothelial function, for the development of TAO, these factors seem to play a role but not a high key role. Hyperhomozysteinemia is said to be related to TAO, but it seems only to be the environmentally acquired hyperhomozysteinemia not the genetically based defect of Methylentetrahydrofolat-Reduktase (MTHFR).<sup><xref ref-type="bibr" rid="bibr17-1076029611435093">17</xref></sup> The genetic defect of nitric oxide synthetase also cannot be found in patients with TAO.</p>
<p>As all the factors influencing endothelial function are the same in people with atherosclerosis and TAO and not a specific one has been identified until now for TAO; and on the contrary, the distribution of these risk factors is even smaller in TAO, and it must be another fact which is crucial in the development of such a severe disorder in a young patients' group. The search should go for a factor which is influencing both endothelial function and endothelium-independent (smooth muscle cell dependent) vasorelaxation.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1076029611435093">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1076029611435093">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029611435093">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Celermajer</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Sorensen</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Gooch</surname>
<given-names>VM</given-names>
</name>
<etal/>
</person-group>. <article-title>Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis</article-title>. <source>Lancet</source>. <year>1992</year>;<volume>340</volume>(<issue>8828</issue>):<fpage>1111</fpage>–<lpage>1115</lpage>.</citation>
</ref>
<ref id="bibr2-1076029611435093">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Eto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Akishita</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Correlation between flow-mediated vasodilatation of the brachial artery and intima-media thickness in the carotid artery in men</article-title>. <source>Arteriosler Thromb Vasc Biol</source>. <year>1999</year>;<volume>19</volume>(<issue>11</issue>):<fpage>2795</fpage>–<lpage>2800</lpage>.</citation>
</ref>
<ref id="bibr3-1076029611435093">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chambers</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>McGregor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jean-Marie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kooner</surname>
<given-names>JS</given-names>
</name>
</person-group>. <article-title>Acute hyperhomocysteinaemia and endothelial dysfunction</article-title>. <source>Lancet</source>. <year>1998</year>;<volume>351</volume>(<issue>9095</issue>):<fpage>36</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr4-1076029611435093">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conklin</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Surowiec</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of nicotine and cotinine on porcine arterial endothelial function</article-title>. <source>J Surg Res</source>. <year>2001</year>;<volume>95</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr5-1076029611435093">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabha</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tanus-Santos</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Toledo</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Cittadino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rocha</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>H</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Transdermal nicotine mimics the smoking-induced endothelial dysfunction</article-title>. <source>Clin Pharmacol Ther</source>. <year>2000</year>;<volume>68</volume>(<issue>2</issue>):<fpage>167</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr6-1076029611435093">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brevetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Martone</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>de Cristofaro</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilatation in patients with peripheral arterial disease</article-title>. <source>Thromb Haemost</source>. <year>2001</year>;<volume>85</volume>(<issue>1</issue>):<fpage>63</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr7-1076029611435093">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laight</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Carrier</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Änggard</surname>
<given-names>EE</given-names>
</name>
</person-group>. <article-title>Antioxidants, diabetes and endothelial dysfunction</article-title>. <source>Cardiovasc Res</source>. <year>2000</year>;<volume>47</volume>(<issue>3</issue>):<fpage>457</fpage>–<lpage>464</lpage>.</citation>
</ref>
<ref id="bibr8-1076029611435093">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gokce</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Duffy</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Hunter</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Keaney</surname>
<given-names>JF</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Vita</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Acute hypertriglyceridemia is associated with peripheral vasodilatation and increased basal flow in healthy young adults</article-title>. <source>Am J Cardiol</source>. <year>2001</year>;<volume>88</volume>(<issue>2</issue>):<fpage>153</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr9-1076029611435093">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duffy</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>ÓBrien</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>New</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Meredith</surname>
<given-names>IT</given-names>
</name>
</person-group>. <article-title>Effect of anti-oxidant treatment and cholesterol lowering on resting arterial tone, metabolic vasodilatation and endothelial function in the human forearm: a randomized, placebo-controlled study</article-title>. <source>Clin Exp Pharmacol Physiol</source>. <year>2001</year>;<volume>28</volume>(<issue>5-6</issue>):<fpage>409</fpage>–<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr10-1076029611435093">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hingorani</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kharbanda</surname>
<given-names>RK</given-names>
</name>
<etal/>
</person-group>. <article-title>Acute systemic inflammation impairs endothelium-dependent dilatation in humans</article-title>. <source>Circulation</source>. <year>1000</year>;<volume>102</volume>(<issue>9</issue>):<fpage>994</fpage>–<lpage>999</lpage>.</citation>
</ref>
<ref id="bibr11-1076029611435093">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leppert</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ringqvist</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Karlberg</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Ringqvist</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Whole-body cooling increases plasma endothelin-1 levels in women with primary Raynaud's phenomenon</article-title>. <source>Clin Physiol</source>. <year>1998</year>;<volume>18</volume>(<issue>5</issue>):<fpage>420</fpage>–<lpage>425</lpage>.</citation>
</ref>
<ref id="bibr12-1076029611435093">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olin</surname>
<given-names>JW</given-names>
</name>
</person-group>. <article-title>Thrombangitis obliterans (Buerger's disease)</article-title>. <source>N Engl J Med</source>. <year>2000</year>;<volume>343</volume>(<issue>12</issue>):<fpage>864</fpage>–<lpage>869</lpage>.</citation>
</ref>
<ref id="bibr13-1076029611435093">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanaka</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Pathology and pathogenesis of Buerger's disease</article-title>. <source>Int J Cardiol</source>. <year>1998</year>;<volume>66</volume>(<issue>suppl 1</issue>):<fpage>237</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr14-1076029611435093">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>MICA gene polymorphism in Takayasu's arteritis and Buerger's disease</article-title>. <source>Int J Cardiol</source>. <year>1998</year>;<volume>66</volume>(<issue>suppl 1</issue>):<fpage>S107</fpage>–<lpage>S113</lpage>.</citation>
</ref>
<ref id="bibr15-1076029611435093">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brodmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Renner</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Stark</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Prothrombotic risk factors in patients with Thrombangitis obliterans</article-title>. <source>Thromb Res</source>. <year>2000</year>;<volume>99</volume>(<issue>5</issue>):<fpage>483</fpage>–<lpage>486</lpage>.</citation>
</ref>
<ref id="bibr16-1076029611435093">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makita</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Komada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kawazoe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hiramori</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thrombangiitis obliterans (Buerger's disease)</article-title>. <source>Circulation</source>. <year>1996</year>;<volume>94</volume>(<issue>9 suppl</issue>):<fpage>II211</fpage>–<lpage>II215</lpage>.</citation>
</ref>
<ref id="bibr17-1076029611435093">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joras</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Poredos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fras</surname>
<given-names>Z</given-names>
</name>
</person-group>. <article-title>Endothelial dysfunction in Buerger's disease and its relation to markers of inflammation</article-title>. <source>Eur J Clin Invest</source>. <year>2006</year>;<volume>36</volume>(<issue>6</issue>):<fpage>376</fpage>–<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr18-1076029611435093">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Idei</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nishioka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Soga</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Vascular function and circulating progenitor cells in thrombangitis obliterans (Buerger's disease) and arteriosclerosis</article-title>. <source>Hypertension</source>. <year>2011</year>;<volume>57</volume>(<issue>1</issue>):<fpage>70</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr19-1076029611435093">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adigüzel</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Akar</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Effects of e NOS and ET-1 polymorphisms in thrombangitis obliterans</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2010</year>;<volume>16</volume>(<issue>1</issue>):<fpage>103</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr20-1076029611435093">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azizi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boutouyrie</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bura-Riviere</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peyrard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Laurent</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fiessinger</surname>
<given-names>JN</given-names>
</name>
</person-group>. <article-title>Thrombangitis obliterans and endothelial function</article-title>. <source>Eur J Clin Invest</source>. <year>2010</year>;<volume>40</volume>(<issue>6</issue>):<fpage>518</fpage>–<lpage>516</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>